Rudy Tanzi is a leading expert on Alzheimer’s disease and has been on the board of ChromaDex, which sells Tru Niagen (NR), for the past two years. He just tweeted:
“We just started a clinical trial of Tru Niagen (nicotinamide riboside) in Alzheimer’s disease at the McCance Center at Mass General Hospital”
ChromaDex started an NR trial with those who have mild cognitive decline and based on their previous publication record, the results should be known next spring.
The Whims of Change 